Antibody-nanoparticle conjugates and methods for making and using such conjugates

US9442107B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9442107-B2
Application numberUS-201514691826-A
CountryUS
Kind codeB2
Filing dateApr 21, 2015
Priority dateApr 27, 2010
Publication dateSep 13, 2016
Grant dateSep 13, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.

First claim

Opening claim text (preview).

We claim: 1. A method for detecting a target molecule in a sample, comprising: (a) contacting the sample with a first antibody that specifically binds to the target molecule; (b) contacting the sample after step (a) with a second antibody conjugated to one or more enzyme molecules, wherein the second antibody specifically binds to the first antibody thereby forming a complex; (c) contacting the complex formed in step (b) above with a third antibody-nanoparticle conjugate wherein the third antibody specifically binds to the second antibody and wherein said third antibody-nanoparticle conjugate comprises three or more metal nanoparticles directly linked to a single third antibody through three or more metal-thiol bonds, wherein the metal-thiol bonds are between thiol of cysteine residues of the antibody and the three or more metal nanoparticles without an intervening linker; (d) contacting the sample after step (c) with a substrate of the enzyme and a metal ion, such that a metal precipitate forms and colocalizes with the target molecule; and (e) detecting the metal precipitate, thereby detecting the target molecule. 2. The method of claim 1 , wherein the target molecule comprises a hapten-labeled nucleic acid probe that specifically binds to the target molecule and wherein the first antibody specifically binds the hapten-labeled nucleic acid probe. 3. The method of claim 1 , wherein the nanoparticles comprise gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof. 4. The method of claim 1 , wherein the metal ion comprises silver ion, gold ion, copper ion, nickel ion, platinum ion, palladium ion, cobalt ion, or iridium ion. 5. The method of claim 1 , further comprising a gold toning step comprising contacting the sample after step (d) with a gold halide salt. 6. The method of claim 5 , wherein the method further comprises amplifying the signal after the gold toning step. 7. The method of claim 6 , wherein the amplifying includes contacting with a silver salt selected from the group consisting of silver nitrate, silver oxide, silver acetate, and silver perchlorate. 8. The method according to claim 1 , further comprising contacting the sample with a reducing agent. 9. The method of claim 8 , wherein the reducing agent comprises sodium thiosulfate. 10. The method according to claim 1 , wherein the metal nanoparticles are about 5 nm or less in diameter. 11. The method according to claim 1 , wherein the single third antibody is directly linked to three to seven nanoparticles through said metal thiol bond without an intervening linker. 12. The method according to claim 1 , wherein the second antibody comprises a goat anti-rabbit immunoglobulin G antibody. 13. The method according to claim 1 , wherein the enzyme comprises an alkaline phosphatase, an acid phosphatase, a β-galactosidase, a β-glucosidase, a β-lactamase, or an esterase. 14. The method of claim 13 , wherein the enzyme is alkaline phosphatase and the substrate of the enzyme comprises 5-bromo-4-chloro-3-indolyl phosphate, ascorbic acid phosphate, or a hydroquinone phosphate derivative. 15. The method of claim 14 , wherein the second antibody is conjugated to three alkaline phosphate molecules. 16. The method according to claim 1 , wherein the target molecule comprises HER2, c-Myc, n-Myc, Abl, EGFR, IGF1R, c-Met, TOP2A, Bcl2, Bcl6, Rb1, p53, or MET.

Assignees

Inventors

Classifications

  • Immunoglobulins · CPC title

  • Acyclic saturated phosphines · CPC title

  • G01N33/531Primary

    Production of immunochemical test materials · CPC title

  • Complexes or chelates of phosphines with metallic compounds or metals · CPC title

  • condensed with carbocyclic rings or carbocyclic ring systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9442107B2 cover?
Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanopa…
Who is the assignee on this patent?
Ventana Med Syst Inc
What technology area does this patent fall under?
Primary CPC classification G01N33/531. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).